The IL17RB Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IL17RB gene in the human KYSE-30 esophageal squamous cell carcinoma cell line. This gene-targeting approach generates a loss-of-function model that enables researchers to dissect the functional role of the IL-25 receptor (IL-17RB) in cancer cell biology and inflammatory signaling networks. The polyclonal format provides a heterogeneous pool of edited cells, reflecting a range of mutations at the target locus and allowing for the study of population-level effects following IL17RB disruption.
The KYSE-30 host cell line was originally derived from a poorly differentiated esophageal squamous cell carcinoma resected from a 64-year-old male Japanese patient. This well-characterized cancer cell line serves as a widely used in vitro model for investigating the molecular mechanisms underlying esophageal carcinoma progression, metastasis, and therapeutic resistance. Its genetic background and tumorigenic properties make it particularly suitable for exploring the contributions of specific genes to the malignant phenotype of esophageal squamous cell carcinoma.
IL17RB encodes the receptor for interleukin-25 (IL-17E), a cytokine that initiates Th2-type immune responses. Upon ligand binding, IL17RB heterodimerizes with IL17RA and recruits the adaptor ACT1 and the E3 ubiquitin ligase TRAF6. This assembly triggers downstream signaling cascades including NF-??B and MAPK pathways, as well as JAK1-mediated STAT3 activation. Consequently, the expression of Th2 effector cytokines such as IL-4, IL-5, and IL-13, and chemokines like CCL11, is upregulated. Upstream regulators of this pathway include TSLP, GATA3, and STAT6, which are known to modulate IL17RB expression and function. The integration of these signals promotes allergic inflammation, tissue remodeling, and potential tumor-microenvironment crosstalk.
In the context of esophageal squamous cell carcinoma, the IL-25/IL17RB axis has been implicated in modulating tumor cell proliferation, migratory capacity, and resistance to chemotherapy. By abrogating IL17RB expression in KYSE-30 cells, this polyclonal knockout model allows for the direct interrogation of these cancer-related phenotypes. Furthermore, the model facilitates studies on how IL17RB-mediated signaling influences the tumor immune microenvironment, potentially revealing novel interactions between esophageal cancer cells and infiltrating immune components that contribute to disease progression.
Researchers can employ this knockout cell population in a variety of functional assays, including western blotting and RT-qPCR to confirm target disruption, cell proliferation and transwell migration assays to assess phenotypic changes, and flow cytometric analysis to evaluate apoptosis. ELISA-based measurement of secreted Th2 cytokines can quantify alterations in downstream effector molecules, while phospho-signaling analysis can map perturbations in NF-??B and MAPK pathways. These applications support target validation studies and drug discovery efforts focused on the IL17RB signaling pathway in esophageal cancer. For additional information, please contact Ascent Research.
